Diabetic Foot Ulcer Clinical Trial
— ASOLO-CWOfficial title:
A Prospective, Open, Non-comparative, Post-market Clinical Follow-up Investigation to Confirm the Safety and Performance of Avance Solo and Avance Solo Adapt NPWT Systems in Low to Moderate Exuding Chronic Wounds
NCT number | NCT04753294 |
Other study ID # | PD-598654 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | June 14, 2021 |
Est. completion date | July 21, 2023 |
Verified date | February 2023 |
Source | Molnlycke Health Care AB |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The primary objective of this post market clinical follow-up (PMCF) investigation is to confirm the safety and performance of Avance®Solo and Avance®Solo Adapt NPWT Systems in low to moderate exuding chronic wounds when used in accordance with the Instructions for Use, for up to 28 days.
Status | Completed |
Enrollment | 136 |
Est. completion date | July 21, 2023 |
Est. primary completion date | July 15, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Male or female = 18 years. 2. Signed written informed consent. 3. Low to moderate exuding chronic wounds (diabetic foot ulcers, venous leg ulcers and pressure ulcers for Avance®Solo or pressure ulcers for Avance®Solo Adapt) suitable for NPWT according to the investigator´s judgement and Instructions for Use. 4. Subjects that will be capable and willing to comply with protocol instructions Exclusion Criteria: 1. Known malignancy in the wound or margins of the wound 2. Untreated and previously confirmed osteomyelitis 3. Non-enteric and unexplored fistulas 4. Necrotic tissue with eschar present 5. Exposed nerves, arteries, veins or organs 6. Exposed anastomotic site 7. Known allergy/hypersensitivity to the dressing or its components. 8. Known pregnancy or planning to become pregnant or lactation at time of study participation. 9. Participation in another investigative drug or device trial currently or within the last 30 days Subjects not suitable for the investigation according to the Investigator's judgement, Clinical Investigation Plan and Instructions for Use |
Country | Name | City | State |
---|---|---|---|
Belgium | Diensthoofd wondkliniek, UZ Gent | Gent | |
Belgium | AZ Delta | Roeselare | |
Denmark | North Zeeland Hospital | Hillerød | |
France | CHU Montpellier | Montpellier | |
Germany | Franziskus-Krankenhaus Berlin | Berlin | |
Germany | Klinik fur Dermatologie, Venerologie und Allergologie Campus Benjamin Franklin | Berlin | |
Germany | Klinikum der Ruhr-Universität Bochum | Bochum | |
Ireland | St James's Hospital | Dublin | |
Italy | Ospedale San Raffaele S.r.I. | Milano | |
Italy | A.O.U. Citta della Salute e della Scienza di Torino - A.O.U. Molinette San Giovanni Battista | Torino | |
Portugal | Santa casa da Misericórdia de Aveiro | Aveiro | |
Portugal | Unidade de Cuidados Continuados António Francisco Guimarães | Guimarães | |
Portugal | Trofa Saúde Hospital Central Hospital da Trofa | Touguinho |
Lead Sponsor | Collaborator |
---|---|
Molnlycke Health Care AB | Syntactx |
Belgium, Denmark, France, Germany, Ireland, Italy, Portugal,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in wound progress | Wound progress compared to last visit and assessed as:
Deteriorated No change Improved |
Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days) | |
Secondary | Wound progress | Wound progress compared between baseline and final visit and assessed as:
Deteriorated No change Improved |
28 days | |
Secondary | Absolute change in wound area | Absolute change in wound area from baseline to all follow-up visits | Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days) | |
Secondary | Absolute change in wound volume | Absolute change in wound volume from baseline to all follow-up visits | Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days) | |
Secondary | Percentage change in wound area | Percentage change in wound area from baseline to all follow-up visits | Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days) | |
Secondary | Percentage change in wound volume | Percentage change in wound volume from baseline to all follow-up visits | Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days) | |
Secondary | Tissue type | Change in tissue type (slough, necrotic, granulation or epithelization) from baseline to all follow-up visits. | Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days) | |
Secondary | Exudate amount | Change in exudate amount using a category scoring system from baseline to all follow-up visits.
Amount: none, low, moderate, or high) |
Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days) | |
Secondary | Exudate nature | Change in exudate nature using a category scoring system from baseline to all follow-up visits.
Nature: serous, fibrinous, serosanguineous, sanguineous, seropurulent, purulent, foul purulent, heamopurulent, or hemorrhagic |
Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days) | |
Secondary | Exudate odor | Change in exudate odor using a category scoring system from baseline to all follow-up visits.
Odor: no odor, slight, moderate, strong, and very strong |
Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days) | |
Secondary | Peri-wound | Change in peri-wound skin condition from baseline to all follow-up visits using the following conditions:
Normal Erythematous Oedematous Eczematous Excoriated Macerated Indurated |
Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days) | |
Secondary | Tissue in-growth | Degree of tissue in-growth when Avance Solo foam is utilized at all follow-up visits as well as extra visits. | Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days) with additional assessments in between when dressing is changed | |
Secondary | Pain assessment | Subject evaluation of pain at Avance Solo dressing or Avance Solo Adapt Film removal using Numeric Rating Scale (NRS) at each follow-up visit. | Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days) | |
Secondary | Trauma | Proportion of subjects with trauma to the wound site and surrounding skin for Avance Solo Border Dressing, fixation strips or Avance Solo Adapt Film at all follow-up visits. | Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days) | |
Secondary | Quality of life assessed using Numeric Rating Scale (NRS) | Impact of everyday life by the systems will be captured through a NRS scale where the subject grade how much the treatment has affected the subject's daily life. 0 is equal to no influence and 10 to considerable influence on everyday life or unbearable.
If replying >0, the subject will state the presence or absence of the following causes: Leakage of dressing Impaired mobility Difficulties in getting dressed Pain Odor |
28 days | |
Secondary | Alarms | Subject evaluation of the system properties (number of sounding alarms) assessed with a given scale at all follow-up visits
0 1-5 6-10 11-15 16-20 More than 20 |
Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days) | |
Secondary | Compliance | Evaluate the compliance to the provided therapy by average number of hours per 24h that the system has not provided treatment since last visit. | Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days) | |
Secondary | Ability to absorb and/or transport exudate via clinical judgement | Evaluation of the Systems ability to absorb and/or transport exudate assessed using a rating scale by the clinician/designee:
Very Poor Poor Good Very Good |
Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days) | |
Secondary | Ease of application | Clinician evaluation of ease of application and removal of Avance®Solo or Avance®Solo Adapt using a Numeric Rating Scale (NRS) collected at baseline, and each follow-up visit. | Baseline, Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days) | |
Secondary | Global satisfaction | Evaluate the investigator and subject global satisfaction of the systems in regards to:
Very dissatisfied Dissatisfied Neither satisfied or dissatisfied Satisfied Very satisfied |
28 days | |
Secondary | Product consumption | Product consumption of the utilized products for the system's, from baseline and final visit using the Avance Solo or Avance Solo Adapt NPWT System | Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days) | |
Secondary | Wear time | Evaluate Avance®Solo or Avance®Solo Adapt wear time in days from baseline to all follow-up visits including potential extra visits | Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04497805 -
Clinical Study of ALLO-ASC-SHEET in Subjects With Diabetic Wagner Grade II Foot Ulcers
|
Phase 2 | |
Withdrawn |
NCT03675269 -
Adjunctive Hyperbaric Oxygen Therapy (HBOT) for Lower Extermity Diabetic Ulcer:
|
N/A | |
Completed |
NCT04624516 -
Effect of Self-foot Exercise on the Incidence of Plantar Foot Diabetic Ulcer Recurrence
|
N/A | |
Not yet recruiting |
NCT06439667 -
VIRTUALLY SUPERVISED TELE-EXERCISE PLATFORM FOR ACCELERATING PLANTAR WOUND HEALING
|
||
Recruiting |
NCT05608187 -
Evaluating Safety and Biological Effect on Wound Healing of ILP100-Topical in Subjects With Diabetic Foot Ulcers
|
Phase 2 | |
Not yet recruiting |
NCT06278935 -
Lifestyle Tailored Offloading for Diabetic Foot Ulcers
|
N/A | |
Not yet recruiting |
NCT06437028 -
Evaluating the Efficacy of Perinatal Membrane Allografts for the Treatment of Diabetic Foot Ulcers.
|
N/A | |
Withdrawn |
NCT05024656 -
AmnioExcel® Plus vs SOC in the Management of Diabetic Foot Ulcers
|
N/A | |
Terminated |
NCT02202668 -
Transcutaneous Raman Spectroscope (TRS) Analyses of Diabetic Foot Ulcers
|
N/A | |
Completed |
NCT01951768 -
Efficacy and Safety of Garamycin® Sponge in Diabetic Patients With a Moderate or Severe Foot Ulcer Infection
|
Phase 4 | |
Terminated |
NCT01966380 -
Proof of Concept (Design Validation) in Patient With Hard to Heal Wounds Such as Pressure Ulcer, Diabetic Foot Ulcer and Leg Ulcer, Leia
|
Phase 2 | |
Completed |
NCT01657474 -
Comparative Study of Two Application Regimens of Amniotic Membrane Wound Graft In the Management of Diabetic Foot Ulcers
|
N/A | |
Active, not recruiting |
NCT00389636 -
TheraGauze™ Alone and Regranex®Gel 0.01% Plus TheraGauze™ in the Treatment of Wagner Stage I Diabetic Foot Ulcers
|
N/A | |
Completed |
NCT01181440 -
Dermagraft(R) for the Treatment of Patients With Diabetic Foot Ulcers
|
Phase 3 | |
Enrolling by invitation |
NCT05888259 -
Plantar Pressure Distribution in Diabetic Foot Ulcer
|
N/A | |
Completed |
NCT04054804 -
Digital Foot Check by Using the D-Foot, a New Software
|
||
Not yet recruiting |
NCT05877378 -
Efficacy of PICO Single-use System in Chronic Ulcers
|
N/A | |
Recruiting |
NCT06037369 -
The Short Message-based Customized Standardized
|
N/A | |
Completed |
NCT03312595 -
Clinical Outcomes After Treatment With RestrataTM Wound Matrix in Diabetic Foot Ulcers (DFU)
|
N/A | |
Recruiting |
NCT04564443 -
A Unique Micro Water Jet Technology Device Versus Standard Debridement in the Treatment of Diabetic Foot
|
N/A |